Gary Gintant, Bernard Fermini, Norman Stockbridge, David Strauss
Index: 10.1016/j.stem.2017.06.005
Full Text: HTML
Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.
ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Supp...
2017-07-13 [10.1016/j.stem.2017.06.004] |
Lineage Tracing: Papers and Progress
2017-07-06 [10.1016/j.stem.2017.06.015] |
Intestinal Enteroendocrine Lineage Cells Possess Homeostatic...
2017-07-06 [10.1016/j.stem.2017.06.014] |
Direct Neuronal Reprogramming: Achievements, Hurdles, and Ne...
2017-07-06 [10.1016/j.stem.2017.06.011] |
Making HSCs on Demand: Looking Ahead
2017-07-06 [10.1016/j.stem.2017.06.010] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved